5 Takeaways After Fed. Circ. Amgen-Sandoz Ruling
The Federal Circuit's first interpretation of key provisions in the Biologics Price Competition and Innovation Act contained vague statements that clouded the ruling's impact on biosimilars and featured stark divisions that...To view the full article, register now.
Already a subscriber? Click here to view full article